Women often resort to the use of drugs and products belonging to complementary and alternative medicine (CAM), including dietary and herbal supplements or phytotherapy, during pregnancy and breastfeeding for the treatment of chronic diseases or for disorders related to or occurring during pregnancy and breastfeeding. However, drugs and CAM products are usually not tested and approved for pregnant or breastfeeding women. Women, especially those of childbearing age and who are pregnant, are usually excluded for randomized clinical trials (RCTs) and therefore evidence of these treatments’ efficacy and safety are predominantly derived from observational studies, anecdotal case reports and case series. Real-world data from clinical toxicology can help define the risk/benefit profile of drugs and CAM products in this population.
With the present Research Topic, we invite experts to submit population-based studies (cohort or case–control studies), drug utilization studies, systematic reviews and meta-analyses, and review articles that contribute to improving the evidence regarding the safety of drugs and CAM products during pregnancy breastfeeding.
All the manuscripts submitted to the collection will need to fully comply with the
Four Pillars of Best Practice in Ethnopharmacology (you can freely download the full version
here). Specifically, it is essential that the composition of the material is described in detail, including a full authentication of the material used, the inclusion of valid species names and a chemical characterization of the preparations used.
Women often resort to the use of drugs and products belonging to complementary and alternative medicine (CAM), including dietary and herbal supplements or phytotherapy, during pregnancy and breastfeeding for the treatment of chronic diseases or for disorders related to or occurring during pregnancy and breastfeeding. However, drugs and CAM products are usually not tested and approved for pregnant or breastfeeding women. Women, especially those of childbearing age and who are pregnant, are usually excluded for randomized clinical trials (RCTs) and therefore evidence of these treatments’ efficacy and safety are predominantly derived from observational studies, anecdotal case reports and case series. Real-world data from clinical toxicology can help define the risk/benefit profile of drugs and CAM products in this population.
With the present Research Topic, we invite experts to submit population-based studies (cohort or case–control studies), drug utilization studies, systematic reviews and meta-analyses, and review articles that contribute to improving the evidence regarding the safety of drugs and CAM products during pregnancy breastfeeding.
All the manuscripts submitted to the collection will need to fully comply with the
Four Pillars of Best Practice in Ethnopharmacology (you can freely download the full version
here). Specifically, it is essential that the composition of the material is described in detail, including a full authentication of the material used, the inclusion of valid species names and a chemical characterization of the preparations used.
